

Chapter 16

REFERENCES

1. Shander A, Knight K, Thurer R, et al. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. *Am J Med.* 2004;116(Suppl 1):58S-69S.
2. Greenburg AG. Pathophysiology of anemia. *Am J Med.* 1996;101(Suppl 2A):7S-11S.
3. Marik PE, Corwin HL. Efficacy of blood transfusion in the critically ill: A systematic review of the literature. *Crit Care Med* 2008;36(9):2667-2674.
4. Prchal JT. Production of erythrocytes. In: Lichtman MA, Kipps TJ, Seligsohn U, et al, eds. *William's Hematology*. 8th ed. New York, NY: McGraw-Hill; 2008:Chapter 31 online text.
5. Doctor A, Stamler JS. Nitric Oxide transport in blood: A third gas in the respiratory cycle. *Compr Physiol.* 2011, 1-28. doi: 10.1002/cphy.c090009
6. Spahn DR, Smith LR, Veronee CD, et al. Acute isovolemic hemodilution and blood transfusion. Effects on regional function and metabolism in myocardium with compromised coronary blood flow. *J Thorac Cardiovasc Surg.* 1993;105(4):694-704.
7. Lund CJ, Donovan JC. Blood volume during pregnancy. *Am J Obstet Gynecol.* 1967;98(3):393-403.
8. Marks PW, Glader B. Approach to anemia in the adult and child. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. *Hematology: Basic Principles and Practice*. 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2008:Chapter 34 online text.
9. Dallman PR, Yip R, Johnson C. Prevalence and causes of anemia in the United States, 1976 to 1980. *Am J Clin Nutr.* 1984;39(3):437-445.
10. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. *JAMA.* 2002;288(12):1499-1507.
11. Prchal JT. Clinical manifestations and classifications of erythrocyte disorders. In: Lichtman MA, Kipps TJ, Seligsohn U, et al, eds. *Williams Hematology*. 8th ed. New York, NY: McGraw-Hill; 2008:Chapter 33 online text.
12. Consensus Conference: Perioperative red blood cell transfusion. *JAMA.* 1988;260(18):2700-2703.
13. Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: Efficacy, risks, alternatives and indications. *Br J Anaesth.* 2005;95(1):33-42.
14. Meyers RL, Paulick RP, Rudolph CD, et al. Cardiovascular responses to acute, severe haemorrhage in fetal sheep. *J Dev Physiol.* 1991;15(4):189-197.
15. Guyton AC, Richardson TQ. Effect of hematocrit on venous return. *Circulation.* 1961;9(1):157-164.
16. Torrance J, Jacobs P, Restrepo A. Intraerythrocytic adaptation to anemia. *N Engl J Med.* 1970;283(4):165-169.
17. Steinberg MH, Benz EJ, Adeloje AH, et al. Pathobiology of the human erythrocyte and its hemoglobins. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. *Hematology: Basic Principles and Practice*. 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2008:Chapter 33 online text.
18. Hébert PC, Van der Linden P, Biro G, et al. Physiologic aspects of anemia. *Crit Care Clin.* 2004;20(2):187-212.
19. Wang P, Ba ZF, Lu MC, Ayala A, Harkema JM, Chaudry IH. Measurement of circulating blood volume in vivo after trauma-hemorrhage and hemodilution. *Am J Physiol.* 1994;266(2):R368-R374.
20. Torres Filho IP, Spiess BD, Pittman RN, Barbee RW, Ward KR. Experimental analysis of critical oxygen delivery. *Am J Physiol Heart Circ Physiol.* 2005;288(3):H1071-H1079.
21. Theye RA, Tuohy GF. Hemodynamics and blood volume during operation with ether anesthesia and unreplaced blood loss. *Anesthesiology.* 1964;25:6-14.
22. Jamnicki M, Kocian R, van der Linden P, Zaugg M, Spahn DR. Acute normovolemic hemodilution: physiology, limitations, and clinical use. *J Cardiothorac Vasc Anesth.* 2003;17(6):747-754.
23. Saxena S, Rabinowitz AP, Johnson C, et al. Iron-deficiency anemia: a medically treatable chronic anemia as a model for transfusion overuse. *Am J Med.* 1993(2);94:120-124.
24. Tsui AKY, Dattani ND, Marsden PA, et al. Reassessing the risk of dilutional anemia: some new pieces to an old puzzle. *Can J Anaesth.* 2010;57(7):779-791.
25. Grande P, Holbek S, Persson J. Microvascular fluid exchange. In: Hahn RG, Prough DS, Svensen SH, eds. *Perioperative Fluid Therapy*. New York, NY: Informa Healthcare USA; 2007:24.
26. Barron M, Wilkes M, Navickis R. A systematic review of the comparative safety of colloids. *Arch Surg.* 2004;139(5):552-563.
27. Hartog B, Bauer B, Reinhart K. The efficacy and safety of colloid resuscitation in the critically ill. *Anesth Analg.* 2011;112:157.
28. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med.* 2004;350(22):2247-2256.
29. Bubojs MJ, Vincent JL. Colloid fluids. In: Hahn RG, Prough DS, Svensen SH, eds. *Perioperative Fluid Therapy*. New York, NY: Informa Healthcare USA; 2007:153-61.
30. Koch C, Li L, Figueiroa P, Mihaljevic T. Transfusion and pulmonary morbidity after cardiac surgery. *Ann Thorac Surg.* 2009;88(5):1410-1418.

31. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*. 1999;340(6):409-417.
32. Shapiro MJ. To filter blood or universal leukoreduction: What is the answer? *Crit Care*. 2004;8(Suppl 2):S27-S30.
33. Hajjar LA, Vincent J, Galas F, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. *JAMA*. 2010;304(14):1559-1567.
34. Bracey AW, Radovancevic R, Riggs SA, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. *Transfusion*. 1999;39(10):1070-1077.
35. Carson JL, Terrin ML, Magaziner L, et al. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). *Transfusion*. 2006;46(12):2192-2206.
36. Heartwire: Post-op anemia in high-CV-risk patients: No CV gains from fixed hemoglobin target in trial. http://www.theheart.org/article/1024017.do#bib_1. Accessed January 3, 2011.
37. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill-current clinical practice in the United States. *Crit Care Med*. 2004;32(1):39-52.
38. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. *JAMA*. 2002;288(12):1499-1507.
39. Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. *JAMA*. 1998;279(3):199-205.
40. Kumar A. Perioperative management of anemia: limits of blood transfusion and alternatives to it. *Clev Clin J Med*. 2009;76(4):S112-S118.
41. Fiebig EW, Busch MP. Infectious risks of transfusion. In: Spiess BD, Spence RK, Shander A, eds. *Perioperative Transfusion Medicine*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:131-152.
42. Dzieczkowski JS, Anderson KC. Transfusion biology and therapy. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. *Harrison's Principles of Internal Medicine*. 17th ed. New York, NY: McGraw-Hill; 2008:Chapter 107 online text.
43. Ashworth A, Klein AA. Cell salvage as part of a blood conservation strategy in anaesthesia. *Br J Anaesth*. 2010;105(4):401-416.
44. Saitenberg S, Petraszko T, Semple E, Branch DR. Transfusion-related acute lung injury (TRALI): a Canadian blood services research and development symposium. *Transfus Med Rev*. 2010;24(4):305-324.
45. Stubbs JR. Transfusion-related acute lung injury, an evolving syndrome: The Road of discovery, with emphasis on the role of the Mayo Clinic. *Transfus Med Rev*. 2011;25(1):66-75.
46. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. *Blood*. 2009;113(15):3406-3417.
47. Waters JH. Perioperative red cell salvage and autotransfusion. In: Spiess BD, Spence RK, Shander A, eds. *Perioperative Transfusion Medicine*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:451-464.
48. Silverman TA, Weiskopf RB. Hemoglobin-based oxygen carriers: Current status and future directions. *Anesthesiology*. 2009;111(5):946-963.
49. Bull BS, Herrmann PC. Morphology of the erythron. In: Lichtman MA, Kipps TJ, Seligsohn U, et al, eds. *Williams Hematology*. 8th ed. New York, NY: McGraw-Hill; 2008:Chapter 29 online text.
50. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. *Ann Thorac Surg*. 2007;83:S27-S86.
51. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of Aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med*. 2008;358(22):2319-2331.
52. Levy JH. Pharmacological approaches to prevent or decrease bleeding in surgical patients. In: Spiess BD, Spence RK, Shander A, eds. *Perioperative Transfusion Medicine*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:403-417.
53. Deleted.
54. Martin K, Wiesner G, Breuer T, et al. The risks of aprotinin and tranexamic acid in cardiac surgery: A one year follow up of 1188 consecutive patients. *Anesth Analg*. 2008;107(6):1783-1790.
55. Mangano DT, Tudor LC, Dietzel C. The risk associated with aprotinin in cardiac surgery. *N Eng J Med*. 2006;354(4):353-365.
56. Karkouti K, Beattie WS, Dattilo K, et al. A propensity score case-controlled comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. *Transfusion*. 2006;46(3):327-338.
57. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness following dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy—a randomised placebo-controlled clinical trial. *J Thrombos Haemostas*. 2009;7(5):795-802.
58. Karlsson M, Ternstrom L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. *Thrombo Haemost*. 2009;102(1):137-144.
59. Eaton WA and Hofrichter J. Hemoglobin S gelation and sickle cell disease. *Blood*. 1987;70(5):1245-1266.
60. Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. *Blood*. 1985;65(1):183-189.
61. Murray DJ. Evaluation of the patient with anemia and coagulation disorders. In: Longnecker DE, Tinker JH, Morgan GE, eds. *Principles and Practice of Anesthesiology*. 2nd ed. Philadelphia, PA: Mosby; 1998:360-378.
62. Noguchi CT, Schechter AN. The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. *Blood*. 1981;58(6):1051-1068.
63. Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. *N Engl J Med*. 1980;302(18):992-995.
64. Firth PG. Anesthesia for peculiar cells—a century of sickle cell disease. *Br J Anaesth*. 2005;95(3):287-299.
65. Keeley KK, Buchanan GR. Acute infarction of long bones in children with sickle cell anemia. *J Pediatr*. 1982;101(2):170-175.
66. Minkin SK, Oh KS, Sanders RC, Siegelman SS. Urologic manifestations of sickle hemoglobinopathies. *South Med J*. 1979;72(1):23-28.

67. Avery EG. Anesthetic considerations in the patient with 1) anemia and 2) coagulopathy. In: Longnecker DE, Brown DL, Newman MF, et al, eds. *Anesthesiology*. New York, NY: McGraw-Hill; 2008:239-266.
68. Kitchens CS. The consultative process. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:3-15.
69. Boggio LN, Kessler CM. Hemophilia A and B. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:45-59.
70. Epocrates online: Hemophilia. <https://online.epocrates.com/u/2911468/Hemophilia/Summary/Highlights>. San Mateo, CA. Accessed January 25, 2011.
71. Rodriguez Merchan EC. The haemophilic pseudotumour. *Int Orthop*. 1995;19(4):255-360.
72. Novoseven: Coagulation Factor VIIa (recombinant). Package insert. Revised September 1999. Bagsvaerd, Denmark. <http://factorviiia.com/pi.pdf>. Accessed January 26, 2011.
73. Rick ME. von Willebrand Disease. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:97-109.
74. Ruggeri ZM, Ware J. von Willebrand factor. *FASEB J*. 1993;7(2):308-316.
75. Roberts HR, Escobar MA. Less common congenital disorders of hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:61-79.
76. MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. *Transfusion*. 2005;45(9):1434-1442.
77. Anwar R, Miloszewski KJ. Factor XIII deficiency. *Br J Haematol*. 1999;107(3):468-494.
78. Riastap Fibrinogen Concentrate (human). Prescribing information. King of Prussia, PA. http://www.riastap.com/docs/RiaSTAP_PI.pdf. Accessed January 9, 2011.
79. Francis CW. Antithrombotic agents. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:449-460.
80. Green JA. Perioperative implications of anticoagulants and antiplatelet therapy. In: Spiess BD, Spence RK, Shander A, eds. *Perioperative Transfusion Medicine*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:389-402.
81. Thomson MICROMEDEX 1.0. Aspirin. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
82. Thomson MICROMEDEX 1.0. Heparin. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
83. Bharadwaj J, Jayaramna C, Shrivastava R. Heparin resistance. *Lab Hematol*. 2003;9(3):125-131.
84. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence based guidelines (3rd edition). *Reg Anesth Pain Med*. 2010;35(1):64-101.
85. Weitz JI. Low-molecular-weight heparins. *N Engl J Med*. 1997;337(10):688-698.
86. Thomson MICROMEDEX 1.0. Low molecular weight heparins. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
87. McDonald SB, Renna M, Spitznagel EL, et al. Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients. *J Cardiothorac Vasc Anesth*. 2005;19(1):4-10.
88. Thomson MICROMEDEX 1.0. Direct thrombin inhibitors. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
89. Koster A, Spiess B, Chew DP, et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. *Am J Cardiol*. 2004;93(3):356-359.
90. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. *J Thorac Cardiovasc Surg*. 2006;131(3):533-539.
91. Thomson MICROMEDEX 1.0. Dabigatran. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
92. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *Br Med J*. 2002;324:71-86.
93. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. *Circulation*. 1999;99(18):2364-2366.
94. Bauer BA. Herbal therapy: What a clinician needs to know to counsel patients effectively. *Mayo Clin Proc*. 2000;75(8):835-841.
95. Magee KA. Herbal therapy: a review of potential health risks and medicinal interactions. *Orthod Craniofac Res*. 2005;8(2):60-74.
96. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: A decision analysis. *Anesth Analg*. 2001;93(3):573-580.
97. Thomson MICROMEDEX 1.0. Abciximab. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
98. Thomson MICROMEDEX 1.0. Tirofiban. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
99. Thomson MICROMEDEX 1.0. Eptifibatide. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
100. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. *Ann Thorac Surg*. 2000;70(3):866-871.
101. Thomson MICROMEDEX 1.0. Clopidogrel. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
102. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. *J Am Coll Cardiol*. 2002;40(2):231-237.
103. Thomson MICROMEDEX 1.0. Ticlopidine. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
104. Thomson MICROMEDEX 1.0. Prasugrel. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
105. Thomson MICROMEDEX 1.0. Dipyridamole. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
106. Thomson MICROMEDEX 1.0. Aggrenox. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
107. Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. *Am J Hematol*. 2004;75(1):40-47.

108. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci.* 1996;143(1-2):1-13.
109. Thomson MICROMEDEX 1.0. Cilostazol. New York. <http://www.thomsonhc.com/home/dispatch>. Accessed January 30, 2011.
110. Vandenbroucke JP, Rosing J, Bloemenkamp K, et al. Oral contraceptives and the risk of venous thrombosis. *N Engl J Med.* 2001;344(20):1527-1535.
111. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. *N Engl J Med.* 2000;342(6):374-380.
112. Heit JA. Thrombophilia: clinical and laboratory assessment and management. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:213-244.
113. Kitchens CS. Surgery and hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:613-634.
114. Koster A, Fischer T, Gruendel M, et al. Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activation. *J Cardiothorac Vasc Anesth.* 17(2):171-175.
115. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. *Thromb Haemost.* 1995;73(1):87-93.
116. Griffin JH, Evatt B, Wideman C, et al. Anticoagulant protein C pathway defective in majority of thrombophilic patients. *Blood.* 1993;82(7):1989-1993.
117. Warkentin TE. Heparin-induced thrombocytopenia. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:421-446.
118. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med.* 344(17):1286-1292.
119. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. *Eur J Haematol.* 2006;76(5):420-426.
120. Zumberg M, Kitchens CS. Purpura and other hematovascular disorders. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:159-182.
121. LaBelle C, Kitchens CS. Disseminated Intravascular Coagulation. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:183-198.
122. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. *JAMA.* 2006;295(9):1050-1057.
123. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. *Blood.* 2002;99(1):36-43.
124. Kim Ritchey A, Keller FG, O'Brien SH. Thromboembolism in nephrotic syndrome. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. *Hematology: Basic Principles and Practice*. 5th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2008:Chapter 162 online text.
125. Khorana AA. Cancer and thrombosis: Implications of published guidelines for clinical practice. *Ann Oncol.* 2009;20(10):1619-1630.
126. Bick RL. Cancer-associated thrombosis. *N Engl J Med.* 2003;349(2):109-111.
127. Moake JL. Thrombotic thrombocytopenic purpura. In: Kitchens CS, Alving BM, Kessler CM, eds. *Consultative Hemostasis and Thrombosis*. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:405-420.